Primoris Services Corporation (NASDAQ:PRIM) has lost 3.27% or $.28 a share to settle at $8.34 with a volume of 38,000 shares, compared to its average three-month volume of 77,000 shares. For the past 52 weeks the stock has been trading between $5.62 and $10 a share. Company has a market capitalization of $398 million.
Primoris Services Corporation (Primoris) is a holding company of various subsidiaries, which form a diversified engineering and construction company providing a range of construction, fabrication, maintenance, replacement and engineering services to public utilities, petrochemical companies, energy companies, municipalities and other customers. The Company provides services in two business segments: Construction Services and Engineering.
The Jones Group (NYSE:JNY) has lost 0.31% or four cents a share to settle at $12.88 with a volume of 750,000 shares compared to its average three-month volume of 1.9 million shares. For the past 52 weeks the stock has been trading between $12.11 and $24.72. Company has a market capitalization of $1.14 billion.
Jones Apparel Group, Inc. is a designer, marketer and wholesaler of branded apparel, footwear and accessories. The Company markets its products to the consumers, through a chain of specialty retail and stores and through its e-commerce Websites. The Company also markets costume jewelry under the Givenchy brand licensed from Givenchy Corporation, women's footwear under the Dockers Women brand licensed from Levi Strauss & Co., and apparel and accessories under the Rachel Roy brand licensed from Rachel Roy IP Company, LLC.
Marina Biotech (NASDAQ:MRNA) has gained 4.34% or three cents a share to settle at $.71 a share with a volume of 1.1 million shares, compared to its average three-month volume of 650,000 shares. For the past 52 weeks the stock has been trading between $.66 a share and $5.96 a share. Company has a current market capitalization of $18.01 million.
Marina Biotech Inc, formerly MDRNA, Inc., is a biotechnology company focused on the discovery, development and commercialization of pharmaceuticals based on RNA interference (RNAi). Its infrastructure provides for pre-clinical scale manufacturing of both siRNAs and delivery materials, the analysis and optimization of these compounds both individually and as drug candidates, and the filing of Investigational New Drug Applications.
Morgans Hotel Group Co. (NASDAQ:MHGC) has lost 5.59% or $.50 a share to settle at $8.52 a share with a volume of 300,000 shares, compared to its average three-month volume of 215,000 shares. For the past 52 weeks the stock has been trading between $4.31 and $11.46 with a current market capitalization of $255 million.
Morgans Hotel Group Co. is a fully integrated hospitality company that operates, owns, acquires, develops and redevelops boutique hotels primarily in gateway cities and select resort markets in the United States, Europe and in select international locations. At December 31, 2009, the Company owned or partially owned, and managed a portfolio of 13 luxury hotel properties in New York, Miami, Los Angeles, San Francisco, London, Las Vegas, Boston and Scottsdale, comprising approximately 4,700 rooms.
Pharmacyclics (NASDAQ:PCYC) has lost 2.51% or $.30 a share to settle at $4.86 a share with a volume of 542,000 shares, compared to its average three-month volume of 420,000. For the past 52 weeks the stock has been trading between $4.75 and $8.60 a share with a current market capitalization of $290 million.
Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. As of June 30, 2010, the Company had four product candidates in clinical development, a clinical development candidate in late-stage preclinical evaluation and several preclinical molecules in lead optimization.
OTCPicks.com is not a registered investment advisers or broker/dealer. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. Always do you own homework before investing in any stock.
Forward-Looking Statement: This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
Disclosure: OTCpicks.com has not been compensated for any current or recent stocks listed in this stock news report
